BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Qiagen receives ARTG inclusion for QIAstat-Dx Meningitis/Encephalitis Panel to support rapid diagnosis in Australia

June 18, 2026 | News

This is the third QIAstat-Dx panel in the Australian Register of Therapeutic Goods (ARTG)



Qiagen has announced that its QIAstat-Dx Meningitis/Encephalitis (ME) Panel has been included in the Australian Register of Therapeutic Goods (ARTG). The inclusion marks rapid molecular testing for the detection of pathogens associated with central nervous system (CNS) infections, supporting timely clinical decision-making in acute care settings.

The QIAstat-Dx ME Panel enables fast detection of 16 common bacterial, viral and fungal pathogens using multiplex PCR from a single cerebrospinal fluid (CSF) sample. These include cytomegalovirus (CMV) and Streptococcus pyogenes, providing actionable diagnostic information for meningitis and encephalitis cases.

Meningitis and encephalitis require timely clinical management and rapid identification of the causative pathogen is important for patient care. Diagnostic delays may increase clinical uncertainty and impact treatment decisions.

The World Health Organization (WHO) has recently issued a strong recommendation for PCR-based testing to ensure the fastest possible detection of pathogens in patients with suspected meningitis. The IVDR compliant QIAstat-Dx ME Panel supports alignment with current guidelines and enables multiplex detection of a range of bacterial, viral and fungal pathogens.

With this latest inclusion, QIAGEN continues to strengthen its QIAstat-Dx syndromic testing portfolio in Australia, complementing the existing QIAstat-Dx Respiratory SARS-CoV-2 Panel and QIAstat-Dx Gastrointestinal Panel.